Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12

Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12

The possibility of using gene therapy for the treatment of prostate cancer is limited by the lack of intravenously administered delivery systems able to safely and selectively deliver therapeutic genes to tumors. Given that lactoferrin (Lf) receptors are overexpressed on prostate cancer cells, we hy...

Full description

Bibliographic Details
Main Authors: Najla Altwaijry, Sukrut Somani, John A. Parkinson, Rothwelle J. Tate, Patricia Keating, Monika Warzecha, Graeme R. Mackenzie, Hing Y. Leung, Christine Dufès
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Drug Delivery
Subjects:
prostate cancer
gene therapy
dendrimer
lactoferrin
nanoparticles
Online Access:http://dx.doi.org/10.1080/10717544.2018.1440666

Internet

http://dx.doi.org/10.1080/10717544.2018.1440666

Similar Items